Current Report Filing (8-k)
June 01 2022 - 4:06PM
Edgar (US Regulatory)
0001782107
false
0001782107
2022-06-01
2022-06-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 1, 2022
Blue Water Vaccines Inc.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-41294 |
|
83-2262816 |
(State or other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
201 E. Fifth Street, Suite 1900 Cincinnati, Ohio |
|
45202 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (513) 620-4101
(Former name or former address, if changed since
last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class |
|
Trading Symbol(s) |
|
Name of Each Exchange on Which Registered |
Common Stock, par value $0.00001 per share |
|
BWV |
|
The Nasdaq Stock Market LLC |
Emerging growth
company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
| Item | 1.01 Entry into Material Definitive Agreement. |
On May 16, 2022, Blue Water Vaccines Inc. (the “Company”)
entered into an amendment (the “Amendment”) of the Agreement for the Sponsorship of a Research Project (the “SRA”),
dated as of December 19, 2019, by and between the Company and The Chancellor Masters and Scholars of the University of Oxford (“Oxford”)
relating to research and optimization of the Company’s universal influenza vaccine candidate, BWV-101, which carried a term of three
years and required aggregate payments of £420,000, which was previously paid by the Company. Pursuant to the Agreement, Oxford is
required to finalize certain pre-clinical studies of the universal influenza vaccine. Pursuant
to the Amendment, the term of the research under the SRA was extended for an additional 18 months, culminating on June 18, 2024. The Company
will also provide additional funding in connection with the research in a sum of £53,500.
The foregoing descriptions
are qualified in their entirety by reference to the SRA and the Amendment, which are filed herewith as Exhibit 10.1 and Exhibit 10.2 hereto
and are incorporated by reference herein.
| Item | 7.01 Regulation FD Disclosure. |
On
May 31, 2022, the Company issued a press release announcing the entry into the Amendment. A copy of the press release is furnished as
Exhibit 99.1 hereto.
The
foregoing information (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and will not be deemed to be filed for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise be subject to the liabilities
of that section, nor will it be deemed to be incorporated by reference in any filing under the Securities Act or the Exchange Act.
| Item | 9.01. Financial Statements and Exhibits. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Blue Water Vaccines Inc. |
|
|
|
Date: June
1, 2022 |
By: |
/s/ Joseph Hernandez |
|
|
Joseph Hernandez |
|
|
Chief Executive Officer |
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Sep 2023 to Sep 2024